FrancophonIA/ELRC3.0 huggingface dataset:
English: Limited data on the effect of hepatic impairment (including Child-Pugh C classification of chronic liver disease) on the pharmacokinetics of posaconazole demonstrate an increase in plasma exposure compared to subjects with normal hepatic function, but do not suggest that dose adjustment is necessary (see sections 4.4 and 5.2).
Croatian: Child-Pugh klasifikaciji) na farmakokinetiku posakonazola pokazuju povećanu izloženost u plazmi u usporedbi s ispitanicima s normalnom funkcijom jetre, ali ne ukazuju na potrebu prilagodbe doze
English: On the first day of treatment take 200 mg (one 5 mL spoonful) once.
Croatian: Prvog dana liječenja uzmite jednu dozu od 200 mg (jednu žličicu od 5 ml).
English: POLAND
Croatian: POLJSKA
English: Other medicines and Posaconazole AHCL
Croatian: Drugi lijekovi i Posakonazol AHCL
English: Additionally, twelve patients 13-17 years of age received posaconazole oral suspension 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899).
Croatian: 600 mg na dan za profilaksu invazivnih gljivičnih infekcija (ispitivanja 316 i 1899).
English: What Posaconazole AHCL is and what it is used for
Croatian: Što se nalazi u ovoj uputi: Što je Posakonazol AHCL i za što se koristi
English: Proportion (%) of patients with proven/probable IFIs On-treatment periodb
Croatian: Kontrolna skupinaa p-vrijednost Udio (%) bolesnika s dokazanom/vjerojatnom IGI
English: Discontinuation of Posaconazole AHCL should be considered if clinical signs and symptoms are consistent with development of liver disease.
Croatian: AHCL u slučaju nastupa kliničkih znakova i simptoma koji ukazuju na razvoj jetrene bolesti.
English: Hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin and/or clinical hepatitis) have been reported during treatment with posaconazole.
Croatian: Tijekom liječenja posakonazolom prijavljene su jetrene reakcije (npr. blagi do umjeren porast vrijednosti ALT-a, AST-a, alkalne fosfataze, ukupnog bilirubina i/ili klinički hepatitis).
English: It should be noted that the relationship between sirolimus trough concentration and AUC is changed during co- administration with posaconazole.
Croatian: Potrebno je naglasiti da se kod istodobne primjene sirolimusa i posakonazola mijenja odnos između najniže koncentracije i AUC-a sirolimusa.
English: What Posaconazole AHCL contains
Croatian: Što Posakonazol AHCL sadrži
English: hepatocellular damage, hepatitis, jaundice, hepatomegaly, cholestasis, hepatic toxicity, hepatic function abnormal
Croatian: hepatocelularno oštećenje, hepatitis, žutica, hepatomegalija, kolestaza, hepatotoksičnost, poremećena funkcija
English: - medicines used to decrease stomach acid such as cimetidine and ranitidine or omeprazole and similar medicines that are called proton pump inhibitors.
Croatian: - efavirenz i fosamprenavir, koji se koriste za liječenje HIV-infekcije. - lijekovi koji smanjuju lučenje želučane kiseline, kao što su cimetidin i ranitidin ili omeprazol i slični lijekovi koji se zovu inhibitori protonske pumpe.
English: Simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513))
Croatian: 6.1 Popis pomoćnih tvari makrogolglicerolhidroksistearat natrijev citrat, dihidrat citratna kiselina hidrat emulzija simetikona (koja sadrži polidimetilsiloksan, polietilenglikol sorbitantristearat, metilcelulozu, silika-gel, polietilenglikol stearat, sorbatna kiselina (E200), benzoatna kiselina (E210) i sulfatna kiselina (E513)) ksantanska guma (E415) natrijev benzoat (E211)
English: Oral posaconazole suspension 800 mg/day in divided doses was evaluated for the treatment of invasive aspergillosis in patients with disease refractory to amphotericin B (including liposomal formulations) or itraconazole or in patients who were intolerant of these medicinal products in a noncomparative salvage therapy trial (Study 0041).
Croatian: U nekomparativnom ispitivanju (Ispitivanje 0041) procjenjivala se posakonazol oralna suspenzija od 800 mg na dan podijeljena u doze kao terapija spašavanja u liječenju invazivne aspergiloze u bolesnika s bolešću otpornom na amfotericin B (uključujući liposomalne formulacije) ili itrakonazol ili u bolesnika koji nisu podnosili te lijekove.
English: Non-Interchangeability between posaconazole tablets and Posaconazole AHCL Oral Suspension The tablet and oral suspension are not to be used interchangeably due to the differences between these two formulations in frequency of dosing, administration with food and plasma drug concentration achieved.
Croatian: Tablete i oralna suspenzija ne smiju se međusobno zamjenjivati zbog razlika u učestalosti doziranja, primjeni uz hranu i postignutim koncentracijama u plazmi između ovih dviju formulacija.
English: §, electrocardiogram abnormal palpitations, bradycardia, supraventricular extrasystoles, tachycardia
Croatian: sindrom produljenog QT-intervala§, odstupanja od normalnih vrijednosti elektrokardiograma§, palpitacije, bradikardija, supraventrikularne ekstrasistole, tahikardija
English: Posaconazole AHCL contains a medicine called posaconazole.
Croatian: Što je Posakonazol AHCL i za što se koristi Posakonazol AHCL sadrži lijek koji se zove posakonazol.
English: Posaconazole AHCL can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them.
Croatian: Posakonazol AHCL može povećati količinu ovih lijekova u krvi, što može dovesti do vrlo ozbiljnih promjena srčanog ritma:
English: OTHER SPECIAL WARNING(S), IF NECESSARY Posaconazole oral suspension and posaconazole tablets are NOT interchangeable.
Croatian: Posakonazol oralna suspenzija i tablete posakonazola NISU međusobno zamjenjivi.
English: How to take Posaconazole AHCL
Croatian: Kako uzimati Posakonazol AHCL
English: Summary of posaconazole oral suspension studies
Croatian: Ispitivanje akonazol oralna suspenzija
English: - fits (convulsions) - nerve damage (neuropathy) - abnormal heart rhythm - shown up on a heart trace (ECG), palpitations, slow or fast heartbeat,
Croatian: - nepravilan srčani ritam - vidi se na elektrokardiogramu (EKG-u), palpitacije, usporen ili ubrzan rad srca, povišen ili snižen krvni tlak
English: Repeat dose administration of posaconazole oral suspension (400 mg twice daily for 16 days) increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 6.7-fold and 8.9-fold (range 3.1 to 17.5-fold), respectively, in healthy subjects.
Croatian: Primjenom ponovljenih doza posakonazol oralne suspenzije (400 mg dva puta na dan tijekom 16 dana) u zdravih se ispitanika Cmax sirolimusa (primijenjenog u jednokratnoj dozi od 2 mg) povećao za prosječno 6,7 puta, a AUC za prosječno 8,9 puta (raspon od 3,1 do 17,5 puta).
English: A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Croatian: PRILOG II. A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: Marketing Authorisation Holder Accord Healthcare S.L.U.
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Accord Healthcare S.L.U.
English: In another study in healthy volunteers, repeat dose administration of posaconazole oral suspension (200 mg twice daily for 7 days) increased the Cmax and AUC of intravenous midazolam (0.4 mg single dose) by an average of 1.3- and 4.6-fold (range 1.7 to 6.4-fold), respectively; Posaconazole oral suspension 400 mg twice daily for 7 days increased the intravenous midazolam Cmax and AUC by 1.6 and 6.2-fold (range 1.6 to 7.6-fold), respectively.
Croatian: U drugom ispitivanju u zdravih dobrovoljaca ponovljena primjena doza posakonazol oralne suspenzije (200 mg dvaput na dan tijekom 7 dana) povećala je Cmax intravenski primijenjenog midazolama (u jednokratnoj dozi od 0,4 mg) za prosječno 1,3 puta, a AUC za prosječno 4,6 puta (raspon od 1,7 do 6,4 puta).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each mL contains 40 mg of posaconazole.
Croatian: Jedan ml sadrži 40 mg posakonazola.
English: If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Posaconazole AHCL.
Croatian: Ako se nešto od gore navedenog odnosi na Vas (ili niste sigurni), obratite se svom liječniku ili ljekarniku prije nego uzmete Posakonazol AHCL.
English: Tell your doctor if you are or think you are pregnant before you start to take Posaconazole AHCL.
Croatian: Ako ste trudni ili mislite da biste mogli biti trudni, obavijestite o tome svog liječnika prije nego počnete uzimati Posakonazol AHCL.
English: NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension posaconazole
Croatian: Uputa o lijeku: Informacije za korisnika Posakonazol AHCL 40 mg/ml oralna suspenzija posakonazol
English: Posaconazole was shown to be non-inferior to fluconazole for clinical success rates at Day 14 as well as 4 weeks after the end of treatment.
Croatian: 4. Pokazalo se da posakonazol nije bio inferioran flukonazolu s obzirom na uspjeh kliničkog odgovora
English: How to store Posaconazole AHCL
Croatian: Kako čuvati Posakonazol AHCL
English: These medicines include: - vincristine, vinblastine and other “vinca alkaloids” (used to treat cancer) - ciclosporin (used during or after transplant surgery) - tacrolimus and sirolimus (used during or after transplant surgery) - rifabutin (used to treat certain infections) - medicines used to treat HIV called protease inhibitors (including lopinavir and atazanavir,
Croatian: - rifabutin (primjenjuje se za liječenje nekih infekcija), - lijekovi koji se primjenjuju za liječenje HIV-infekcije, a zovu se inhibitori proteaze (uključujući lopinavir i atazanavir koji se primjenjuju s ritonavirom), - midazolam, triazolam, alprazolam i drugi benzodiazepini (primjenjuju se kao sredstva za umirenje ili opuštanje mišića),
English: oedema, pain, chills, malaise, chest discomfort, drug intolerance, feeling jittery, mucosal inflammation
Croatian: edem, bol, zimica, opće loše osjećanje, nelagoda u prsištu, nepodnošenje lijeka, osjećaj nervoze, upala sluznica
English: - if you have an abnormal heart rhythm tracing (ECG) that shows a problem called long QTc interval - if you have a weakness of the heart muscle or heart failure - if you have a very slow heartbeat - if you have heart rhythm disturbance - if you have any problem with potassium, magnesium or calcium levels in your blood - if you are taking vincristine, vinblastine and other “vinca alkaloids” (medicines used to treat cancer).
Croatian: - ako imate bilo koji poremećaj razine kalija, magnezija ili kalcija u krvi - ako uzimate vinkristin, vinblastin ili druge vinka alkaloide (lijekove koji se primjenjuju za liječenje raka).
English: Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5).
Croatian: halofantrina ili kinidina, jer može doći do povećanja koncentracije ovih lijekova u plazmi te time do produljenja QTc-intervala, a u rijetkim slučajevima i do pojave torsades de pointes (vidjeti dijelove 4.4 i 4.5).
English: vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth,
Croatian: povraćanje, bol u abdomenu, proljev, dispepsija, suha usta, flatulencija, konstipacija, anorektalna nelagoda
English: The active substance is posaconazole.
Croatian: Djelatna tvar je posakonazol.
English: hepatic failure, hepatitis cholestatic, hepatosplenomegaly, liver tenderness, asterixis Skin and subcutaneous tissue disorders Common:
Croatian: jetre zatajenje jetre, kolestatski hepatitis, hepatosplenomegalija, osjetljivost jetre, asteriksis
English: Ear and labyrinth disorder Rare:
Croatian: Poremećaji bubrega i mokraćnog sustava Manje često:
English: See “Other medicines and Posaconazole AHCL” below for more information including information on other medicines which may interact with Posaconazole AHCL.
Croatian: Za informacije o drugim lijekovima koji mogu imati međusobno djelovanje s lijekom Posakonazol
English: Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole.
Croatian: Tijekom istodobne primjene s posakonazolom preporučuje se učestalo nadziranje bolesnika zbog mogućih nuspojava i reakcija toksičnosti povezanih s antiretrovirusnim lijekovima koji su supstrati enzima CYP3A4.
English: Uncommon: the following may affect up to 1 in 100 people - anaemia - signs include headaches, feeling tired or dizzy, being short of breath or looking pale and a low level of haemoglobin shown up in blood tests - low level of platelets (thrombocytopenia) shown in blood tests - this may lead to bleeding - low level of “leukocytes” a type of white blood cell (leukopenia) shown in blood tests - this can make you more likely to get infections - high level of “eosinophils” a type of white blood cell (eosinophilia) - this can happen if you have inflammation - inflammation of the blood vessels - heart rhythm problems
Croatian: - nizak broj krvnih pločica (trombocitopenija), što se vidi na krvnim pretragama - to može dovesti do krvarenja - nizak broj leukocita, vrste bijelih krvnih stanica (leukopenija), što se vidi na krvnim pretragama;
English: Clinical success rates in Oropharyngeal Candidiasis Endpoint
Croatian: Tablica 4. Postotak kliničkog uspjeha u liječenju kandidijaze usta i ždrijela
English: Repeat dose administration of fosamprenavir (700 mg twice daily x 10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
Croatian: Primjena ponovljenih doza fosamprenavira (700 mg dvaput na dan tijekom 10 dana) s oralnom suspenzijom posakonazola (200 mg jedanput na dan prvog dana, 200 mg dvaput na dan drugog dana, a zatim 400 mg dvaput na dan sljedećih 8 dana) snizila je Cmax posakonazola za 21%, a AUC za 23%.
English: First time treatment of Thrush
Croatian: Prvo liječenje mliječca
English: Strawberry flavour (containing propylene glycol)
Croatian: - velike ljubičaste mrlje na koži (trombotička trombocitopenijska purpura)
English: Concomitant use of posaconazole and phenytoin and similar inducers (e.g. carbamazepine, phenobarbital, primidone) should be avoided unless the benefit to the patient outweighs the risk.
Croatian: Istodobnu primjenu posakonazola i fenitoina i njima sličnih induktora (npr. karbamazepina, fenobarbitala,
English: It can also be given with an infusion pump.
Croatian: Također se može primjenjivati infuzijskom pumpom.
English: This means that it is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Croatian: To znači da je vrlo sličan biološkom lijeku (poznatom kao „referentni lijek”) koji je već odobren u Europskoj uniji (EU).
English: Severe hypoglycaemia can lead to loss of consciousness and, in very extreme cases, to death.
Croatian: Teška hipoglikemija može uzrokovati gubitak svijesti i u iznimno ozbiljnim slučajevima, smrt.
English: The doctor should instruct the patient on how to use the medicine properly.
Croatian: Liječnik bi trebao informirati bolesnika o ispravnoj primjeni lijeka.
English: In addition, studies have shown that both medicines produce similar levels of the active substance in the body.
Croatian: Osim toga, ispitivanja su pokazala da oba lijeka proizvode slične razine djelatne tvari u tijelu.
English: Hypoglycaemia may be due to the medicine itself or other factors such as diet and exercise.
Croatian: Hipoglikemija može biti uzrokovana samim lijekom ili drugim čimbenicima, kao što su režim prehrane i vježbanje.
English: In some circumstances, such as when blood acid levels are dangerously high (ketoacidosis), the medicine may be given into a vein.
Croatian: U nekim okolnostima, poput opasno visokih razina kiseline u krvi (ketoacidoza), lijek se može primijeniti u venu.
English: It helps control blood glucose levels, thereby alleviating symptoms and reducing the risk of complications of diabetes.
Croatian: On pomaže u kontroli razine glukoze u krvi, čime se uklanjaju simptomi i smanjuje se rizik od komplikacija šećerne bolesti.
English: The full EPAR for Insulin lispro Sanofi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Insulin lispro Sanofi nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In diabetes, patients have high levels of blood glucose either because the body does not produce enough insulin or the body is unable to use insulin effectively.
Croatian: Bolesnici koji boluju od šećerne bolesti imaju visoke razine glukoze u krvi zato jer tijelo ne proizvodi dovoljne količine inzulina ili ne može učinkovito iskoristiti inzulin.
English: In one study, in patients with type 1 diabetes, HbA1c reduced by 0.44 and 0.46 percentage points with Insulin lispro Sanofi and Humalog respectively after 26 weeks; in the second study, in patients with type 2 diabetes, the corresponding figures were 0.93 versus 0.88 percentage points.
Croatian: U jednom ispitivanju, u bolesnika s dijabetesom tipa 1, HbA1c je smanjen za 0,44 i 0,46 postotna boda nakon 26 tjedana primjene lijeka Insulin lispro Sanofi, odnosno lijeka Humalog; u drugom ispitivanju, u bolesnika s dijabetesom tipa 2, odgovarajući rezultati iznosili su 0,93, odnosno 0,88 postotna boda.
English: In addition, studies show that both medicines have similar effects in reducing blood glucose levels and similar side effects.
Croatian: Osim toga, ispitivanja su pokazala da oba lijeka imaju sličan učinak smanjivanja razine glukoze u krvi i slične nuspojave.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements for biosimilar medicines, Insulin lispro Sanofi has a highly similar structure, purity and biological activity to Humalog and is distributed in the body in the same way.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je da, u skladu sa zahtjevima EU-a za bioslične lijekove, lijek Insulin lispro Sanofi ima vrlo sličnu strukturu, čistoću i biološku aktivnost kao i lijek Humalog te se u tijelu raspoređuje na isti način.
English: Because Insulin lispro Sanofi is a fast-acting insulin, it is usually given shortly before a meal and, when necessary, soon after a meal.
Croatian: Budući da je lijek Insulin lispro Sanofi brzodjelujući inzulin, uglavnom se daje neposredno prije jela i, kada je potrebno, nedugo nakon jela.
English: Insulin lispro Sanofi is a medicine used to control blood glucose (sugar) levels in adults and children with diabetes who need insulin.
Croatian: Insulin lispro Sanofi je lijek koji se primjenjuje za kontrolu razine glukoze (šećera) u krvi u odraslih osoba i djece oboljelih od šećerne bolesti kojima je potreban inzulin.
English: The active substance in Insulin lispro Sanofi is a form of insulin which is absorbed more quickly by the body than human regular insulin, and can therefore act faster.
Croatian: Djelatna tvar lijeka Insulin lispro Sanofi oblik je inzulina koji tijelo apsorbira brže od običnog ljudskog inzulina te stoga može brže djelovati.
English: This is a summary of the European public assessment report (EPAR) for Insulin lispro Sanofi.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni lijeka (EPAR) za lijek Insulin lispro Sanofi.
English: Two further studies in a total of 1,012 patients compared Insulin lispro Sanofi with Humalog and found them to be similarly effective at reducing blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose levels are controlled over time.
Croatian: U dvama dodatnim ispitivanjima na ukupno 1 012 bolesnika u kojima je uspoređen lijek Insulin lispro Sanofi s lijekom Humalog utvrđeno je da oba lijeka imaju sličnu djelotvornost u smanjivanju razine tvari naziva glikozilirani hemoglobin (HbA1c) u krvi, što pokazuje koliko se dobro kontrolira razina glukoze u krvi tijekom vremena.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Insulin lispro Sanofi have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Insulin lispro Sanofi nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Insulin lispro Sanofi is a ‘biosimilar medicine'.
Croatian: Insulin lispro Sanofi je „biosličan lijek”.
English: Insulin lispro Sanofi may cause hypoglycaemia (low blood glucose levels) and must not be given to patients whose blood glucose is already low.
Croatian: Lijek Insulin lispro Sanofi može uzrokovati hipoglikemiju (niska razina glukoze u krvi) te se ne smije davati bolesnicima s niskom razinom glukoze u krvi.
English: For more information about treatment with Insulin lispro Sanofi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Insulin lispro Sanofi pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svojem liječniku ili ljekarniku.
English: What measures are being taken to ensure the safe and effective use of Insulin lispro Sanofi?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Insulin lispro Sanofi?
English: The dose of Insulin lispro Sanofi is worked out for each patient and depends on the patient's blood glucose level.
Croatian: Doza lijeka Insulin lispro Sanofi prilagođava se za svakog bolesnika i ovisi o razini glukoze u krvi u bolesnika.
English: Therefore, the CHMP's view was that, as for Humalog, the benefits of Insulin lispro Sanofi outweigh its risks and recommended that it be given marketing authorisation.
Croatian: Stoga je stav CHMP-a da koristi od lijeka Insulin lispro Sanofi nadmašuju identificirane rizike, kao i za Humalog, te je preporučio davanje odobrenja za stavljanje lijeka u promet.
English: For the full list of all side effects and restrictions with Insulin lispro Sanofi, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Insulin lispro Sanofi potražite u uputi o lijeku.
English: The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution.
Croatian: Referentni lijek za lijek za Insulin lispro Sanofi je lijek Humalog 100 jedinica/ml otopina.
English: Laboratory studies comparing Insulin lispro Sanofi with the reference medicine Humalog have shown that the active substance in Insulin lispro Sanofi is highly similar in terms of structure, purity and biological activity to that of Humalog.
Croatian: Laboratorijska ispitivanja u kojima je lijek Insulin lispro Sanofi uspoređen s lijekom Humalog pokazala su da postoji velika sličnost između djelatne tvari lijeka Insulin lispro Sanofi i djelatne tvari lijeka Humalog u pogledu strukture, čistoće i biološke aktivnosti.
English: For practical information about using Insulin lispro Sanofi, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Insulin lispro Sanofi bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: Insulin lispro Sanofi is given as an injection under the skin in the upper arm, thigh, buttock or belly.
Croatian: Lijek Insulin lispro Sanofi primjenjuje se injekcijom pod kožu u nadlakticu, bedro, stražnjicu ili trbuh.
English: Insulin lispro Sanofi insulin lispro
Croatian: Insulin lispro Sanofi inzulin lispro
English: It is not intended to provide practical advice on how to use Insulin lispro Sanofi.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Insulin lispro Sanofi.
English: What is Insulin lispro Sanofi and what is it used for?
Croatian: Što je Insulin lispro Sanofi i za što se koristi?